Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IV IL-2 in Metastatic Renal Cell Carcinoma
NCT00002846Phase 2Unknown
- Sponsor
- Levine Cancer Institute
- Start
- Sep 1995
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in renal cell carcinoma (RCC), sponsored by Levine Cancer Institute. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00002846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002846.